Cystic fibrosis (CF) manifests as a clinical syndrome characterized by chronic sinopulmonary infection as well as by gastrointestinal, nutritional, and other abnormalities.
Lung damage secondary to chronic infection is the main determinant of morbidity and mortality in individuals with cystic fibrosis. CF individuals are highly susceptible to bacterial infections in the respiratory tract and repeated and intensive antibiotic therapy is required to maintain lung function and quality of life and reduce exacerbations in infected patients.
According to a study conducted by Jeffrey et al., 2002 it is estimated that 80–95% of patients with CF succumb to respiratory failure brought on by chronic bacterial infection and concomitant airway inflammation. Cystic fibrosis occurs in males and females with approximately equal frequencies, though clinically male patients have slightly better health than female patients.
Cystic fibrosis (CF) is an inherited disease, which causes problems in the body’s cells that make salt, water, and mucus. There is no cure for CF. It is a disease that gets worse over time. But better treatments can now help people to live a longer and healthier life.
CF individuals are highly susceptible to bacterial infections in the respiratory tract and repeated and intensive antibiotic therapy is required to maintain lung function and quality of life and reduce exacerbations in infected patients.
Inhaled antibiotics have been used as a treatment for CF respiratory tract infections since penicillin first became available. Fosfomycin tobramycin (FTI) for inhalation has activity against anaerobic, gram-negative, and gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
The treatment of multidrug-resistant gram-negative bacteria in patients with CF with advanced lung disease is challenging given the intrinsic resistance of these organisms to antimicrobials of several different classes.
A number of different oral and intravenous antibiotics may be combined to tailor antibiotic therapy as best as possible to particular combinations of positive bacterial culture results.
As molecular diagnostics for a wider range of bacteria in the CF airway microbiome become available, better clinical trials are needed to inform the choice of antibiotics for long-term bacterial suppression and treatment.
Key players, such as Insmed Incorporated, Aridis Pharma, etc., are involved in developing therapies for the treatment of Chronic Lung Infections in Cystic Fibrosis. Arikayce (Insmed Incorporated), AR-501 (Aridis Pharma), and along with other compelling treatment options in the clinical trials is expected to increase the overall market size of Chronic Lung Infections in Cystic Fibrosis.